Status:
RECRUITING
Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Bone Fracture
Glucose, High Blood
Eligibility:
FEMALE
50-70 years
Brief Summary
Breast cancer is the most common cancer type in European women. Patients treated for early non-metastatic breast cancer comprise a growing group of survivors due to early diagnosis and improved treatm...
Detailed Description
Purpose and background Breast cancer is the most common cancer in Danish women, and has an average of 4,750 new cases a year (1). Patients treated for early (non-metastatic) breast cancer (EBC) compri...
Eligibility Criteria
Inclusion
- Postmenopausal
- Breast cancer stage I-III
- Eligible to receive (neo-)adjuvant chemotherapy/other antineoplastic treatment
Exclusion
- Prior malignancy
- Metabolic disease (diabetes mellitus etc)
Key Trial Info
Start Date :
December 17 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03784651
Start Date
December 17 2018
End Date
November 1 2026
Last Update
September 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Danmark, Denmark, 2100